Page last updated: 2024-12-07
ethylene glycol methacrylate phosphate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
ethylene glycol methacrylate phosphate: improves viability of encapsulated human stem cell preparations [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 90551 |
| CHEMBL ID | 3186093 |
| SCHEMBL ID | 41531 |
| MeSH ID | M0496354 |
Synonyms (45)
| Synonym |
|---|
| pm 100 |
| 2-phosphonooxyethyl 2-methylprop-2-enoate |
| oligo (2-(methacryloxy)ethylphosphonic acid) |
| ethylene glycol methacrylate phosphate |
| 2-(phosphonooxy)ethyl methacrylate |
| monomethacryloylethyl phosphate |
| eg-mcp cpd |
| 24599-21-1 |
| qaa91b09ko , |
| 2-propenoic acid, 2-methyl-, 2-(phosphonooxy)ethyl ester |
| unii-qaa91b09ko |
| einecs 246-342-6 |
| NCGC00256268-01 |
| dsstox_rid_80611 |
| dsstox_gsid_44951 |
| tox21_301277 |
| dsstox_cid_24951 |
| cas-52628-03-2 |
| 35705-94-3 |
| ethylene glycol, dihydrogen phosphate methacrylate |
| 2-hydroxyethyl methacrylate acid phosphate |
| acid phosphoxyethyl methacrylate |
| mono(methacryloyloxyethyl) phosphate |
| ethylene glycol monomethacrylate monophosphate |
| light ester p 1m |
| phosmer m |
| 2-phosphoethyl methacrylate |
| 2-methacryloyloxyethyl phosphate |
| jamp 514 |
| mono(2-(2-methyl-2-propenoyloxy)ethyl) phosphate |
| 2-(methacryloyloxy)ethyl dihydrogen phosphate |
| mono(2-(methacryloyloxy)ethyl) phosphate |
| 2-methacryloyloxyethyl acid phosphate |
| mono(2-methacryloyloxyethyl) acid phosphate |
| methacrylic acid, 2-hydroxyethyl ester dihydrogen phosphate |
| kayamer pm 1 |
| SCHEMBL41531 |
| 2-methacryloxyethyl phosphoric acid |
| CHEMBL3186093 |
| DTXSID70274211 |
| FT-0750137 |
| SEILKFZTLVMHRR-UHFFFAOYSA-N |
| ethylene glycol methacrylate phosphate (contains up to 25% of diester), stab. with 0.1% mehq |
| mfcd00128921 |
| Q27287167 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 0.5359 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 21.3333 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 75.6936 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.59
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.59) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||